| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Milligan Michael Lee | Title: Chief Financial Officer & Principal Accounting Officer | C/O NEUMORA THERAPEUTICS, INC., 260 ARSENAL WAY, SUITE 1, WATERTOWN | /s/ Michael Lee Milligan | 19 Feb 2026 | 0001993953 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NMRA | Common Stock | Sale | $5,119 | -1,436 | -6.4% | $3.56 | 21,034 | 17 Feb 2026 | Direct | F1 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on August 30, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation. |
Title: Chief Financial Officer & Principal Accounting Officer